274 related articles for article (PubMed ID: 16322336)
1. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
[TBL] [Abstract][Full Text] [Related]
2. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
Sijanovic S; Karner I
Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
Florkowski CM; Brownlie BE; Elliot JR; Ayling EM; Turner JG
N Z Med J; 1993 Oct; 106(966):443-4. PubMed ID: 8233173
[TBL] [Abstract][Full Text] [Related]
4. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women.
Sajjinanont T; Rajchadara S; Sriassawaamorn N; Panichkul S
J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S71-6. PubMed ID: 16858944
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma.
Görres G; Kaim A; Otte A; Götze M; Müller-Brand J
Eur J Nucl Med; 1996 Jun; 23(6):690-2. PubMed ID: 8662104
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
[TBL] [Abstract][Full Text] [Related]
7. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.
Jódar E; Begoña López M; García L; Rigopoulou D; Martínez G; Hawkins F
Osteoporos Int; 1998; 8(4):311-6. PubMed ID: 10024900
[TBL] [Abstract][Full Text] [Related]
8. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.
Appetecchia M
Horm Res; 2005; 64(6):293-8. PubMed ID: 16269872
[TBL] [Abstract][Full Text] [Related]
9. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
De Rosa G; Testa A; Maussier ML; Callà C; Astazi P; Albanese C
Horm Metab Res; 1995 Nov; 27(11):503-7. PubMed ID: 8770627
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
11. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
Panico A; Lupoli GA; Fonderico F; Marciello F; Martinelli A; Assante R; Lupoli G
Thyroid; 2009 May; 19(5):437-42. PubMed ID: 19415993
[TBL] [Abstract][Full Text] [Related]
12. The long term effect of levothyroxine on bone mineral density in patients with well differentiated thyroid carcinoma after treatment.
Eftekhari M; Asadollahi A; Beiki D; Izadyar S; Gholamrezanezhad A; Assadi M; Fard-Esfahani A; Fallahi B; Takavar A; Saghari M
Hell J Nucl Med; 2008; 11(3):160-3. PubMed ID: 19081859
[TBL] [Abstract][Full Text] [Related]
13. The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma.
Kim MK; Yun KJ; Kim MH; Lim DJ; Kwon HS; Song KH; Kang MI; Baek KH
Bone; 2015 Feb; 71():101-5. PubMed ID: 25445448
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density and bone microarchitecture after long-term suppressive levothyroxine treatment of differentiated thyroid carcinoma in young adult patients.
Mendonça Monteiro de Barros G; Madeira M; Vieira Neto L; de Paula Paranhos Neto F; Carvalho Mendonça LM; Corrêa Barbosa Lima I; Corbo R; Fleiuss Farias ML
J Bone Miner Metab; 2016 Jul; 34(4):417-21. PubMed ID: 26056020
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma.
Reverter JL; Colomé E; Holgado S; Aguilera E; Soldevila B; Mateo L; Sanmartí A
Endocrine; 2010 Jun; 37(3):467-72. PubMed ID: 20960170
[TBL] [Abstract][Full Text] [Related]
16. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
Marcocci C; Golia F; Vignali E; Pinchera A
J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
[TBL] [Abstract][Full Text] [Related]
17. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
Ongphiphadhanakul B; Puavilai G; Rajatanavin R
J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of bone density in women after thyroid cancer surgery and treatment with suppressive doses of L-thyroxine].
Jurecka-Tuleja B; August R; Kukulska A; Bartnikowa W; Deja R; Czernik E; Handkiewicz-Junak D
Wiad Lek; 2001; 54 Suppl 1():378-82. PubMed ID: 12182053
[TBL] [Abstract][Full Text] [Related]
19. [The risk factors and bone mineral density in women on long-term levothyroxine treatment].
López Alvarez MB; Hawkins F; Rigopoulou D; Martínez G; Jodar E; Estenoz J; Ortuño B; Arnaiz F
Med Clin (Barc); 1999 Jan; 112(3):85-9. PubMed ID: 10074614
[TBL] [Abstract][Full Text] [Related]
20. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women.
Kung AW; Lorentz T; Tam SC
Clin Endocrinol (Oxf); 1993 Nov; 39(5):535-40. PubMed ID: 8252741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
